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Abstract
Background: Several studies have now examined the effects of selective serotonin reuptake inhibitor (SSRI)
treatment on brain function in a variety of anxiety disorders including obsessive-compulsive disorder (OCD),
posttraumatic stress disorder (PTSD), and social anxiety disorder (social phobia) (SAD). Regional changes in
cerebral perfusion following SSRI treatment have been shown for all three disorders. The orbitofrontal cortex
(OFC) (OCD), caudate (OCD), medial pre-frontal/cingulate (OCD, SAD, PTSD), temporal (OCD, SAD, PTSD)
and, thalamic regions (OCD, SAD) are some of those implicated. Some data also suggests that higher perfusion
pre-treatment in the anterior cingulate (PTSD), OFC, caudate (OCD) and antero-lateral temporal region (SAD)
predicts subsequent treatment response. This paper further examines the notion of overlap in the neurocircuitry
of treatment and indeed treatment response across anxiety disorders with SSRI treatment.
Methods:  Single photon emission computed tomography (SPECT) using Tc-99 m HMPAO to assess brain
perfusion was performed on subjects with OCD, PTSD, and SAD before and after 8 weeks (SAD) and 12 weeks
(OCD and PTSD) treatment with the SSRI citalopram. Statistical parametric mapping (SPM) was used to compare
scans (pre- vs post-medication, and responders vs non-responders) in the combined group of subjects.
Results: Citalopram treatment resulted in significant deactivation (p = 0.001) for the entire group in the superior
(t = 4.78) and anterior (t = 4.04) cingulate, right thalamus (t = 4.66) and left hippocampus (t = 3.96). Deactivation
(p = 0.001) within the left precentral (t = 4.26), right mid-frontal (t = 4.03), right inferior frontal (t = 3.99), left
prefrontal (3.81) and right precuneus (t= 3.85) was more marked in treatment responders. No pattern of baseline
activation distinguished responders from non-responders to subsequent pharmacotherapy.
Conclusions: Although each of the anxiety disorders may be mediated by different neurocircuits, there is some
overlap in the functional neuro-anatomy of their response to SSRI treatment. The current data are consistent
with previous work demonstrating the importance of limbic circuits in this spectrum of disorders. These play a
crucial role in cognitive-affective processing, are innervated by serotonergic neurons, and changes in their activity
during serotonergic pharmacotherapy seem crucial.
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Background
Significant advances in our understanding of the mediat-
ing psychobiology and the development of effective treat-
ments for anxiety disorders have been made in recent
years. Modern brain imaging techniques have proved use-
ful in exposing specific albeit overlapping neurocircuitry
that underlies individual anxiety disorders [1,2]. How-
ever, relatively little work has focused on the extent to
which the anxiety disorders overlap with respect to
changes in brain perfusion that accompany response to
first-line treatment that is after all pharmacologically sim-
ilar for different disorders.
The selective serotonin reuptake inhibitors (SSRIs) are
currently recommended as first line medications for most
anxiety disorders, including obsessive-compulsive disor-
der (OCD) [3], posttraumatic stress disorder [4] and
social anxiety disorder [5]. A number of imaging studies
have now examined the effects of SSRI's on brain per-
fusion in individual anxiety disorders. In OCD, attenua-
tion of pre-treatment regional activation has been shown
to correlate with treatment response in the anterolateral
orbitofrontal cortex (OFC), caudate nucleus, thalamus,
and temporal regions [6-11]. Results for studies assessing
pre-treatment cerebral perfusion as a predictor of
response, have, however, yielded mixed results. In some,
an inverse relationship appears to exist with pre-treatment
regional activation of the OFC [12], anterior cingulate,
caudate [6] and subsequent responses to treatment. Con-
versely findings of higher prefrontal, cingulate and basal
ganglia activation correlating with subsequent treatment
response have also been reported [13,14]. In OCD co-
morbid with depression, substrates of response to the
SSRI, paroxetine, appear to differ based on pretreatment
[15] activation patterns as well as changes that accompany
treatment response when an SSRI is given in identical
doses for either of the two conditions separately [16].
In social anxiety disorder SSRI treatment response accom-
panies attenuation of frontal, anterior and lateral tempo-
ral cortex, cingulate, and thalamic activity [17,18]. Higher
anterior and lateral temporal cortical perfusion at baseline
correlated with subsequent treatment response in the
former study. The latter study also demonstrated some
overlap of regions demonstrating attenuation of activity
for both cognitive and pharmacotherapy interventions.
In PTSD, a single study by our group demonstrated medial
temporal lobe deactivation with treatment irrespective of
clinical response and medial prefrontal cortex activation
correlated with treatment response. In addition, no base-
line differences distinguished responders and non-
responders to subsequent SSRI treatment [19].
In this present study, we hypothesised firstly, that
response to SSRI treatment in this combined group of sub-
jects with anxiety disorders (OCD, PTSD, SAD) would
effect shared changes in rCBF affecting primarily limbic
and related prefrontal regions and thus suggest some over-
lap between disorders in the mechanism of their response
to effective treatment with SSRI's. Secondly, pre-treatment
differences in regional perfusion would likely differentiate
responders to subsequent treatment with citalopram
across the anxiety disorders.
Methods
Subjects
Adult subjects with a primary diagnosis of OCD (n = 11),
PTSD (n = 11) or SAD (n = 15) were recruited from the
Anxiety Disorders Clinic of our tertiary hospital. All sub-
jects were interviewed with the Structured Clinical Inter-
view for the Diagnosis of Axis-I Disorders [20] to ascertain
diagnosis according to DSM-IV criteria. Results for the
PTSD group have been reported previously [19].
Comorbid major depression was an exclusion criterion in
the OCD and SAD, but not in the PTSD subjects. Never-
theless, in all cases comorbid disorders were considered
secondary in terms of temporal course, symptom severity,
and associated distress. Patients previously treated with
SSRI's had been free of medication for a minimum of four
weeks for fluoxetine and two weeks for other SSRI's. In
total 30 (81%) of the group were SSRI naïve. Subjects with
other central nervous system disorders including previous
head injury or epilepsy were excluded. The Institutional
Review Board of our University approved the protocol
and all patients gave informed written consent after a full
explanation of the possible risks and benefits.
Pharmacotherapy and measures
All patients underwent treatment with citalopram, the
most selective of the currently available selective serot-
onin reuptake inhibitors (SSRIs). The duration of the trial
of treatment was 12 weeks for OCD and PTSD, and 8
weeks for SAD.
Dosage was initiated at 20 mg daily for the first two weeks
and then maintained at 40 mg daily for the remainder of
the study. Measures of symptom improvement were made
bi-weekly by clinicians using the Clinical Global Impres-
sions (CGI) scale [21]. Subjects with a CGI change score
of 2 or less post-treatment were defined as responders,
while those with scores greater than 2 were defined as
non-responders.
Anxiety symptoms were also rated using disorder specific
scales including the Liebowitz Social Anxiety Scale(LSAS)
[22], the Yale Brown Obsessive-Compulsive Scale
(YBOCS) [23] and the Clinician Administered Scale forBMC Psychiatry 2004, 4:30 http://www.biomedcentral.com/1471-244X/4/30
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PTSD [24]. Depressive symptoms were rated using the
Montgomery-Asberg Depression Rating Scale (MADRS)
[25].
SPECT imaging
Single photon emission computed tomography (SPECT)
was conducted before and after pharmacotherapy. Sub-
jects lay supine in a quiet dimly lit room for 30 minutes
prior to injection of the radiopharmaceutical. Apart from
administration of the injection by a physician, they
remained alone in the room during this period. Subjects
were asked to remain at rest during the 30 minute period
and for 10 minutes after injection of the
radiopharmaceutical.
An injection of 555 MBq (15 mCi) of technetium-99 m
hexamethylpropylene amine oxime (Tc-99 m HMPAO)
was given into an arm vein through a previously placed
intravenous cannula. After completion of the rest period,
SPECT imaging of the brain was performed, with the sub-
ject's head supported by a headrest, using a dual detector
gamma camera (Elscint, Helix, GE Medical Systems, USA)
equipped with fan beam collimators.
Data were acquired in the step-and-shoot mode, using a
360 degree circular orbit, with the detectors of the gamma
camera as close as possible to the subject's head. The
height of the imaging table and radius of rotation were
noted for each subject and the same measurements were
used for the follow-up study. Data were acquired using a
128 × 128 image matrix in 3 degree steps of 15 seconds
per step.
Data were reconstructed by filtered backprojection, using
a Metz filter (power = 5, FWHM = 14 mm) and a zoom
factor of 2.29. The Chang (1978) method was used for
attenuation correction. Scatter correction was not per-
formed. The final reconstructed pixel size was 3.87 mm by
3.87 mm. Image files were converted from interfile to ana-
lyze format using conversion software (Medcon, Erik
Nolf, UZ Ghent).
Stastical analyses were conducted on a voxel-by-voxel
basis using the Statistical Parametric Mapping (SPM99,
Wellcome Department of Cognitive Neurology, UK) [26].
The realign function was used to co-register baseline and
posttreatment SPECT images for each subject and to gen-
erate a mean image for each subject. Realigned images
were then normalised to the Montreal Neurological Insti-
tute (MNI) standard anatomical space to a value of 50
using proportional scaling. For this the transform func-
tion from the mean image for each subject to the normal-
ised image with 4 mm3  voxels using 12 affine
transformations and 7 × 8 × 7 non-linear basis functions
was used. Standardised images were then smoothed using
a Gaussian kernel with a FWHM of 12 mm3.
A multi-group study design was performed using 2 groups
(responders and non-responders) with 2 conditions each
(pre- and post-treatment). Contrasts were applied to look
for areas of significant change post-treatment compared to
pre-treatment. Contrasts were also used to search for areas
of relative change in treatment responders compared to
non-responders. A second design was employed to com-
pare the baseline scans of responders to SSRI pharmaco-
therapy with those of non-responders. Contrasts were
used to search for regions of significant differences on the
baseline scans of responders compared to non-respond-
ers.
In view of a priori knowledge suggesting involvement of
the cingulate, hippocampus, inferior frontal cortex, and
striatum in the anxiety disorders, an uncorrected p-value
of p < 0.001 corresponding to a t value of 3.34, was cho-
sen for the analysis of these regions in order to minimize
type I errors. Given the relative paucity of data in this area,
we chose this uncorrected p-value, based on work using a
similar methodology [19]. In order to minimize type I
errors a significance level of p < 0.05 corrected for Gaus-
sian Random Field Theory was used for the remainder of
the brain. A spatial extent threshold of 5 voxels was also
used at all times. Masking using a threshold proportional
to 0.4 times the mean voxel value was used to minimize
the analysis of voxels not located in grey matter. Further-
more, clusters were ignored if co-registration with a
SPECT template demonstrated that they were located out-
side of grey matter.
Results
Twenty-two males and fifteen females with a mean age of
33.5 years (SD 9.8) completed the study. Clinical changes
with pharmacotherapy for each disorder are provided in
Table 1. This shows that for each of the anxiety disorders
being studied, citalopram was effective in significantly
reducing clinical measures of severity as determined by a
CGI change score of 2 or less (much or very much
improved). As such, 20 of 37 patients (54%) were
responders to citalopram.
Comparison of pre- and post-treatment scans for the
whole group showed decreased activity in 4 significant
clusters in grey matter (Figure 1): These included the supe-
rior cingulate, right thalamus, anterior cingulate, and the
left hippocampus (Table 2). Comparison of pre- and post-
medication scans showed no significant areas of
activation.
Comparison of responders with non-responders demon-
strated that responders had a significantly greater decreaseBMC Psychiatry 2004, 4:30 http://www.biomedcentral.com/1471-244X/4/30
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of activity in 4 clusters (Figure 2). These clusters were
localised to the left precentral, right middle frontal, right
inferior frontal and, left prefrontal regions (Table 3).
Comparison of baseline scans of responders and non-
responders did not reveal any significant differences.
Discussion
The main finding of this paper was that citalopram phar-
macotherapy resulted in significant deactivation within
anterior and superior cingulate cortex, the left hippocam-
pus and the right thalamus in a combined group of
patients with different anxiety disorders (OCD, PTSD, and
SAD). Furthermore, deactivation was significantly more
apparent in responders than in non-responders to SSRI
treatment within precentral, right inferior, middle frontal
and left prefrontal regions. Interestingly, no pre-treatment
differences in regional perfusion between subsequent
treatment responders vs non-responders were found.
Although there are important differences in the symp-
tomatology of the anxiety disorders, these conditions do
share certain aspects of their phenomenology, including
heightened anxiety and avoidance behaviour. Further-
more, previous functional brain imaging work has dem-
onstrated overlapping neurocircuitry across different
anxiety disorders with activation of paralimbic circuitry
and right inferior frontal cortex in a combined group com-
prising subjects with OCD, PTSD, and specific phobia [1].
Results in the present study now also point to an overlap
in the functional neuroanatomy, primarily implicating
paralimbic neurocircuitry, in treatment response to the
same SSRI, citalopram, across anxiety disorders. In citalo-
pram responders, effects across disorders were most pro-
nounced in the mid, inferior and prefrontal cortex. In
other regions, such as the striatum, data on treatment
response and symptom provocation seems to indicate less
overlap across anxiety disorders, which may suggest only
partial and regionally specific overlap between disorders
[1,2].
Specific limbic regions are well-known to play a role in
broadly mediating anxiety. Early observations of epilep-
togenic cingulate lesions support its role in regulating
affect [27]. Furthermore, recent work has suggested a role
for the anterior cingulate in integrating cognitive and
motivational processes. These include evaluating environ-
mental cues and monitoring performance [28] On the
other hand, a central role for the hippocampus in contex-
tual aspects of fear conditioning has been demonstrated
[29,30].
The findings here complement previous studies of OCD,
PTSD, and SAD that have demonstrated a specific role for
the cingulate and hippocampus in these conditions. Stud-
ies in OCD have shown increased anterior cingulate activ-
ity at baseline, or deactivation during pharmacotherapy
with serotonergic agents [31]. In PTSD, anterior cingulate
activity is also increased in some, although not all, studies
of PTSD [32,33] Further, the anterior cingulate is deacti-
vated during citalopram treatment of SAD patients [17].
Dysfunction of the hippocampus, as indicated by smaller
hippocampal volume and declarative memory deficits,
may play an important role in PTSD [34].
The medial prefrontal cortex comprises several related
areas including anterior cingulate cortex. Lesions of this
area are associated with suboptimal responses to stress,
and the area has important inhibitory inputs to the amy-
gdala which mediate extinction of fear conditioning [29].
The middle and inferior frontal cortex, on the other hand,
is involved in encoding and retrieval of verbal memories.
Our finding that the right inferior frontal cortex was more
Table 1: Clinical parameters for all the groups (mean ± SD), (paired t-test).
Baseline Endpoint p
OCD (n = 11) YBOCS 26.6 ± 4.7 23.7 ± 5.8 0.001
MADRS 13.64 ± 9.6 9.9 ± 6.4 0.119
CGI-severity 4.7 ± 0.647 4.18 ± 1.1 0.025
CGI-improvement 3.1 ± 0.7
SAD (n = 15) LSAS 79.2 ± 30.2 63.1 ± 28.5 0.003
MADRS 15 ± 4.9 9.1 ± 5.9 0.004
CGI-severity 4.6 ± 0.8 3.3 ± 1.1 0.001
CGI-improvement 2.7 ± 1.2
PTSD (n = 11) CAPS 78.1 ± 16.9 45.5 ± 23.9 <0.01
MADRS 25 ± 6.7 15.9 ± 8.0 <0.01
CGI -severity 4.5 ± 0.5 2.5 ± 0.7 <0.01
CGI-improvement 1.9 ± 0.7
YBOCS, Yale Brow Obsessive-compulsive scale; MADRS, Montgomery Asberg Depression Rating scale; CGI-s, Clinical global impressions severity; 
CGI-I, Clinical global impressions – improvement; LSAS, Liebowitz Social Anxiety Scale; CAPS, Clinician Administered PTSD scale.BMC Psychiatry 2004, 4:30 http://www.biomedcentral.com/1471-244X/4/30
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Combined group deactivation following treatment with citalopram Figure 1
Combined group deactivation following treatment with citalopram. Regions of deactivation for the combined group 
of OCD + SAD + PTSD following treatment with citalopram. Significant grey matter clusters are seen in the superior cingulate, 
anterior cingulate, left medial temporal region (hippocampus).
Table 2: Localisation of significant clusters of deactivation following treatment for the combined group of OCD, SAD, PTSD. Zmax set 
to threshold of t = 3.34 corresponding to p < 0.001
Cluster size (voxels) t MNI co-ordinates (x,y,z) Brain region
44 4.78 -4,12,36 Superior cingulate
19 4.66 24,-28,12 Right thalamus
10 4.04 0,48,8 Anterior cingualate
7 3.96 -24,-12,-20 Left hippocampusBMC Psychiatry 2004, 4:30 http://www.biomedcentral.com/1471-244X/4/30
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Regional deactivation (responders > non-responders) Figure 2
Regional deactivation (responders > non-responders). Grey matter clusters of greater deactivation in responders vs 
non-responders were detected in the left precentral, prefrontal and right mid - and inferior-frontal regions.
Table 3: Localisation of significant clusters of deactivation in responders vs non-responders to SSRI treatment for the combined group 
of OCD, SAD, PTSD. Zmax set to threshold of t = 3.34 corresponding to p < 0.001
Cluster size (voxels) t MNI co-ordinates (x,y,z) Brain region
21 4.26 -24,-20,56 Left precentral
33 4.03 12,64,-8 Right mid-frontal
17 3.99 36,32,-20 Right inferior frontal cortex
5 3.85 8,-48,16 Right precuneus
18 3.81 -28,60,-8 Left prefrontalBMC Psychiatry 2004, 4:30 http://www.biomedcentral.com/1471-244X/4/30
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deactivated in responders is perhaps consistent with pre-
vious findings showing increased activity pre-treatment in
this region across different anxiety disorders [2] and in
some, but not all, studies of PTSD [35].
Serotonergic circuits innervate the medial prefrontal cor-
tex and other limbic structures, and chronic administra-
tion of a serotonin reuptake inhibitor may lead to an
increase in their neurotransmission. It is possible that the
medial prefrontal cortex deactivation during serotonergic
pharmacotherapy indicates that a compensatory increase
of activity in this region is no longer needed after symp-
tom improvement. Along these lines, a number of func-
tional and electrophysiological imaging studies of
depression have found that anterior cingulate hyperactiv-
ity predicts a positive response to pharmacotherapy, a
finding that has also been interpreted as indicating the
baseline presence of an adaptive compensatory response
[36]. In addition changes in cognitive processing of fron-
tal cortex may be secondary to symptom reduction caused
by primary drug-induced changes within the limbic sys-
tem. We have previously demonstrated similarly higher
pre-treatment prefrontal perfusion in subsequent
responders relative to non-responders using inositol in
OCD [37]. Interestingly, inositol responsive disorders
overlap with those responsive to SSRI's which may suggest
that it is serotonergic components of these disorders that
account for at least some of the overlap in perfusion pat-
terns demonstrated here.
In contrast, however, increased activity in anterior cingu-
late or orbitofrontal region in OCD has also been shown
to predict a poorer response to pharmacotherapy [9].
Perhaps increased activity in particular limbic circuits
plays a different functional role in different psychiatric
disorders. Only limited functional imaging studies of
pharmacotherapy effects have involved provocation para-
digms [38] and such differences in design may account for
certain inconsistencies across studies. Alternatively, it is
feasible that different effects in different disorders may
also help explain inconsistencies. In the current dataset,
however, we were unable to demonstrate any associations
between baseline activity and pharmacotherapy response
for the combined group.
This study is limited by the slightly different inclusion cri-
teria (inclusion of secondary depression in PTSD group)
and pharmacotherapy duration for different disorders.
While the absence of untreated controls may to some
extent limit the conclusions we can draw, comparing non-
responders to responders we believe serves as a reasonable
evaluation of changes that result from treatment response.
The lower spatial resolution of SPECT may be considered
a limitation nevertheless this study usefully emphasizes
the importance of limbic regions (amygdala, hippocam-
pus) in mediating anxiety. Furthermore, deactivation
within these regions as well as richly connected frontal
regions following SSRI treatment, particularly in respond-
ers, is clearly demonstrated. Further research combining
pharmacological interventions and functional methodol-
ogies, and using tracers tailored to specific neurotransmit-
ter receptors, will undoubtedly lead to increased
understanding of the pathogenesis of the anxiety disor-
ders and the mechanisms of response to treatment in the
future.
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